Delphine Loirat

ScholarGPS® ID: 87205593059770

Affiliation

Institut Curie, France

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

107

Predicted Citations

4,074

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases (journal article) De Moura, Alexandre \| Loirat, Delphine \| Vaillant, Sarah \| Korbi, Sinen \| Kiavue, Nicolas \| Bello Roufai, Diana \| Escalup, Laurence \| Desmaris, Romain \| Vaflard, Pauline \| Cottu, Paul \| ... \| Acramel, Alexandre Breast Cancer, volume 31, issue 4, pages 572-580 (2024). 10.1007/s12282-024-01565-7 Cited by (2) \| Cite \| Source
TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer. (journal article) Cabel, Luc \| Loirat, Delphine \| Martin Babau, Jerome \| Bello, Diana \| Pierga, Jean-Yves \| Lerebours, Florence \| Ezzili, Cyrine \| Berger, Frederique \| Bidard, Francois Clement Journal of Clinical Oncology, volume 42, issue 16_suppl, pages TPS1142-TPS1142 (2024). 10.1200/JCO.2024.42.16_suppl.TPS1142 Cite \| Source
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis (journal article) Vasseur, Antoine \| Cabel, Luc \| Hego, Caroline \| Takka, Wissam \| Trabelsi Grati, Olfa \| Renouf, Benjamin \| Lerebours, Florence \| Loirat, Delphine \| Brain, Etienne \| Cottu, Paul \| ... \| Bidard, François-Clément Oncogene, volume 43, issue 16, pages 1214-1222 (2024). 10.1038/s41388-024-02986-6 Cite \| Source
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial (journal article) Diéras, Véronique \| Han, Hyo S. \| Wildiers, Hans \| Friedlander, Michael \| Ayoub, Jean-Pierre \| Puhalla, Shannon L. \| Loirat, Delphine \| Ratajczak, Christine \| Adamu, Hephzibah \| Girardi, Vincent \| Arun, Banu K. European Journal of Cancer, volume 200 (2024). 10.1016/j.ejca.2024.113580 Cited by (2) \| Cite \| Source
Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience (journal article) Tison, Thais \| Loap, Pierre \| Arnaud, Emilie \| Cao, Kim \| Bringer, Solene \| Kissel, Manon \| Maaradji, Safia \| Mainguene, Juliette \| Pierga, Jean-Yves \| Lerebours, Florence \| ... \| Kirova, Youlia M. Advances in Radiation Oncology, volume 9, issue 3, pages 101384- (2024). 10.1016/j.adro.2023.101384 Cited by (1) \| Cite \| Source
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy (journal article) Bardia, Aditya \| Pusztai, Lajos \| Albain, Kathy \| Ciruelos, Eva Maria \| Im, Seock-Ah \| Hershman, Dawn \| Kalinsky, Kevin \| Isaacs, Claudine \| Loirat, Delphine \| Testa, Laura \| ... \| Sharma, Priyanka Therapeutic Advances in Medical Oncology, volume 16 (2024). 10.1177/17588359241248336 Cite \| Source
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab (journal article) Seban, Romain-David \| Arnaud, Emilie \| Loirat, Delphine \| Cabel, Luc \| Cottu, Paul \| Djerroudi, Lounes \| Hescot, Segolene \| Loap, Pierre \| Bonneau, Claire \| Bidard, Francois-Clement \| ... \| Buvat, Irene European Journal of Nuclear Medicine and Molecular Imaging, volume 50, issue 13, pages 4024-4035 (2023). 10.1007/s00259-023-06394-y Cited by (4) \| Cite \| Source
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial (journal article) Rugo, Hope S \| Bardia, Aditya \| Marmé, Frederik \| Cortés, Javier \| Schmid, Peter \| Loirat, Delphine \| Trédan, Olivier \| Ciruelos, Eva \| Dalenc, Florence \| Gómez Pardo, Patricia \| ... \| Tolaney, Sara M The Lancet, volume 402, issue 10411, pages 1423-1433 (2023). 10.1016/S0140-6736(23)01245-X Cited by (75) \| Cite \| Source
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program (journal article) de Moura, Alexandre \| Vuagnat, Perrine \| Renouf, Benjamin \| Pierga, Jean-Yves \| Loirat, Delphine \| Vaflard, Pauline \| Lafayolle de la Bruyère, Charline \| Chaumard-Billotey, Natacha \| Hajjaji, Nawale \| Ladoire, Sylvain \| ... \| Bidard, François-Clément Scientific Reports, volume 13, issue 1 (2023). 10.1038/s41598-023-40569-9 Cited by (2) \| Cite \| Source
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). (journal article) Tolaney, Sara M. \| Bardia, Aditya \| Marmé, Frederik \| Cortés, Javier \| Schmid, Peter \| Loirat, Delphine \| Tredan, Olivier \| Ciruelos, Eva M \| Dalenc, Florence \| Gómez Pardo, Patricia \| ... \| Rugo, Hope S. Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 1003-1003 (2023). 10.1200/JCO.2023.41.16_suppl.1003 Cited by (15) \| Cite \| Source
216P Sacituzumab govitecan in metastatic triple-negative breast cancer: Efficacy -with a focus on brain metastases- and toxicity in a real-world cohort (journal article) Loirat, D. \| De Moura, A. \| Korbi, S. \| Kiavue, N. \| Escalup, L. \| Desmaris, R. \| Cabel, L. \| Vaflard, P. \| Cottu, P.H. \| Pierga, J-Y. \| ... \| Acramel, A. ESMO Open, volume 8, issue 1, pages 101405- (2023). 10.1016/j.esmoop.2023.101405 Cited by (1) \| Cite \| Source
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy (journal article) Bardia, A. \| Pusztai, L. \| Albain, K. \| Kalinsky, K. \| Hershman, D. \| Barlow, W. \| Tokunaga, E. \| Ciruelos, E.M. \| Loirat, D. \| Isaacs, C. \| ... \| Sharma, P. The Breast, volume 68 (2023). 10.1016/S0960-9776(23)00137-6 Cite \| Source
Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer (journal article) Loap, Pierre \| Nicaise, Benjamin \| Laki, Fatima \| Loirat, Delphine \| Pierga, Jean-Yves \| Fourquet, Alain \| Kirova, Youlia Strahlentherapie und Onkologie, volume 199, issue 1, pages 30-37 (2023). 10.1007/s00066-022-01960-z Cite \| Source
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer (journal article) Loap, Pierre \| Loirat, Delphine \| Berger, Frederique \| Rodrigues, Manuel \| Bazire, Louis \| Pierga, Jean-Yves \| Vincent-Salomon, Anne \| Laki, Fatima \| Boudali, Latifa \| Raizonville, Laurence \| ... \| Kirova, Youlia JAMA Oncology, volume 8, issue 12, pages 1802- (2022). 10.1001/jamaoncol.2022.5074 Cited by (28) \| Cite \| Source
Concurrent Olaparib with Radiotherapy in Patients with Triple Negative Breast Cancer: Final Results of the RADIOPARP Phase 1 Trial (journal article) Loap, P. \| Loirat, D. \| Berger, F. \| Rodrigues, M. \| Bazire, L. \| Pierga, J.Y. \| Vincent-Salomon, A. \| Laki, F. \| Boudali, L. \| Raizonville, L. \| ... \| Kirova, Y. International Journal of Radiation OncologyBiologyPhysics, volume 114, issue 3, pages S43-S44 (2022). 10.1016/j.ijrobp.2022.07.411 Cite \| Source
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (journal article) Rugo, Hope S. \| Bardia, Aditya \| Marmé, Frederik \| Cortes, Javier \| Schmid, Peter \| Loirat, Delphine \| Trédan, Olivier \| Ciruelos, Eva \| Dalenc, Florence \| Pardo, Patricia Gómez \| ... \| Tolaney, Sara M. Journal of Clinical Oncology, volume 40, issue 29, pages 3365-3376 (2022). 10.1200/JCO.22.01002 Cited by (117) \| Cite \| Source
LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) (journal article) Rugo, H.S. \| Bardia, A. \| Marmé, F. \| Cortés, J. \| Schmid, P. \| Loirat, D. \| Tredan, O. \| Ciruelos, E.M. \| Dalenc, F. \| Gomez Pardo, P. \| ... \| Tolaney, S.M. Annals of Oncology, volume 33 (2022). 10.1016/j.annonc.2022.08.012 Cited by (43) \| Cite \| Source
214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study (journal article) Schmid, P. \| Cortés, J. \| Marmé, F. \| Rugo, H.S. \| Tolaney, S.M. \| Oliveira, M. \| Loirat, D. \| Jhaveri, K. \| Yoon, O.K. \| Motwani, M. \| ... \| Bardia, A. Annals of Oncology, volume 33 (2022). 10.1016/j.annonc.2022.07.253 Cited by (18) \| Cite \| Source
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (journal article) O’Shaughnessy, Joyce \| Brufsky, Adam \| Rugo, Hope S. \| Tolaney, Sara M. \| Punie, Kevin \| Sardesai, Sagar \| Hamilton, Erika \| Loirat, Delphine \| Traina, Tiffany \| Leon-Ferre, Roberto \| ... \| Cortés, Javier Breast Cancer Research and Treatment, volume 195, issue 2, pages 127-139 (2022). 10.1007/s10549-022-06602-7 Cited by (21) \| Cite \| Source
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (journal article) Rugo, Hope S. \| Tolaney, Sara M. \| Loirat, Delphine \| Punie, Kevin \| Bardia, Aditya \| Hurvitz, Sara A. \| O’Shaughnessy, Joyce \| Cortés, Javier \| Diéras, Véronique \| Carey, Lisa A. \| ... \| Kalinsky, Kevin npj Breast Cancer, volume 8, issue 1 (2022). 10.1038/s41523-022-00467-1 Cited by (35) \| Cite \| Source